Sumatriptan

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3552
R7053		 Yusuf (Control exposed to Naratriptan), 2018 Elective abortions 1st trimester retrospective cohort (claims database) exposed to other treatment, sick Adjustment: No 1.06 [0.49;2.29] C 136/3,496   7/190 143 3,496
ref
S3488
R6725		 Ephross (Control exposed to Naratriptan), 2014 Induced abortions during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 1.47 [0.19;11.28] C 16/626   1/57 17 626
ref
S3532
R6982		 O'Quinn, 1999 Elective abortions 1st trimester prospective cohort unexposed, sick Adjustment: No 0.24 [0.01;5.02] C 0/76   2/92 2 76
ref
Total 3 studies 1.02 [0.50;2.05] 162 4,198
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yusuf (Control exposed to Naratriptan), 2018Yusuf, 2018 1 1.06[0.49; 2.29]1433,49683%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ephross (Control exposed to Naratriptan), 2014Ephross, 2014 2 1.47[0.19; 11.28]1762612%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA O'Quinn, 1999O'Quinn, 1999 0.24[0.01; 5.02]2765%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.02[0.50; 2.05]1624,1980.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Control exposed to Naratriptan; 2: Control exposed to Naratriptan;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.02[0.50; 2.05]1624,1980%NAYusuf (Control exposed to Naratriptan), 2018 Ephross (Control exposed to Naratriptan), 2014 O'Quinn, 1999 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.24[0.01; 5.02]276 -NAO'Quinn, 1999 1 exposed to other treatment, sickexposed to other treatment, sick 1.10[0.53; 2.27]1604,1220%NAYusuf (Control exposed to Naratriptan), 2018 Ephross (Control exposed to Naratriptan), 2014 2 Tags Adjustment   - No  - No 1.02[0.50; 2.05]1624,1980%NAYusuf (Control exposed to Naratriptan), 2018 Ephross (Control exposed to Naratriptan), 2014 O'Quinn, 1999 3 All studiesAll studies 1.02[0.50; 2.05]1624,1980%NAYusuf (Control exposed to Naratriptan), 2018 Ephross (Control exposed to Naratriptan), 2014 O'Quinn, 1999 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Out of scale0.24[0.01; 5.02]276 -NAO'Quinn, 1999 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.10[0.53; 2.27]1604,1220%NAYusuf (Control exposed to Naratriptan), 2018 Ephross (Control exposed to Naratriptan), 2014 20.510.01.0